Western Blot: XIAP Antibody - Unpurified [NB100-56183] - Analysis of XIAP in various tumor cell lines using this antibody at 1:2000.
Immunohistochemistry-Paraffin: XIAP Antibody - Unpurified [NB100-56183] - Human breast carcinoma using this antibody at 1:2000. A-A3, successively higher magnifications of the breast carcinoma tissue section. ...read more
Western Blot: XIAP Antibody - Unpurified [NB100-56183] - XIAP Antibody [NB100-56183] - Analysis of recombinant full-length IAP proteins using this antibody to XIAP at 1:2000. The data shows that the antibody recognizes ...read more
Recombinant BIR2 domain protein fragment of human XIAP was used as immunogen. The BIR2 domain used for immunogen corresponds to amino acids 163-230 of human XIAP (Deveraux et al, 1999).
The antibody recognizes epitopes in the BIR2 domain of XIAP. Therefore it can recognize full-length XIAP and XIAP cleavage fragments containing the BIR2 domain. However, XIAP cleavage fragments may be biologically unstable, and therefore cleavage fragments may be difficult to detect.
Test in a species/application not listed above to receive a full credit towards a future purchase.
XIAP [human X-linked IAP, hILP (human IAP-like protein), MIHA, BIRC4) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria-dependent and independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including XIAP, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubiquitination (Morizane et al, 2005). Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. XIAP is highly characterized with respect to its structure and biochemical mechanisms and has received interest as a therapeutic target (reviewed in Schimmer, 2006). Since XIAP blocks a substantial portion of the apoptosis pathway and is associated with chemoresistance in cancer cells, inhibiting XIAP has been a focus for potential therapeutics. Approaches have included antisense oligonucleotides and small molecule inhibitors. Small molecules that that target the BIR2 and BIR3 domains of XIAP are considered particularly attractive. This is because the BIR domains inhibit caspase activity, and it is thought that removing the inhibition should increase the cell's ability to undergo apoptosis as well as decrease its potential for chemoresistance. Full-length human XIAP is a 497 amino acid protein and migrates at approx. 53 kDa on SDS-PAGE.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The Ins and Outs of Survivin By Rachel M.A. Linger, Ph.D.What is survivin?Survivin is a small (16.5 kDa) protein normally found in human fetal tissue. In contrast, survivin is typically undetectable in most normal adult tissues. Expression of... Read full blog post.
Caspase 9 - an important apoptosis marker Caspases are essential mediators of programmed cell death and are needed for both the induction of apoptosis as well as for aiding the degradation of cellular structures. Initiator caspases (such as Caspase-9) sense and respond to various signals i... Read full blog post.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.